Navigation Links
Jeff Aronin Named One of the 20 Most Influential Leaders in Healthcare for 2018
Date:10/1/2018

Paragon Biosciences CEO Jeff Aronin was recently recognized by Insights Care magazine for his innovative leadership in the biosciences sector and for his work bringing life-altering drugs to patients in need. Jeff’s vision has led Paragon to the top of the industry with over 32 Novel and New Drug Approvals earned by the R&D teams now at Paragon and its portfolio companies.

From his inspiration as a young professional to his role as a leading industry executive, Insights Care highlighted how Jeff “strived to merge his work with his passion for bringing innovative therapies to people living with severe conditions with high unmet medical need.” For his core therapeutic areas including neurology, Jeff Aronin’s pharmaceutical companies have earned more NDA approvals than any other company during the past 10 years, including the largest pharmaceutical companies in the world.

“From my earliest days, the opportunity to meet with patients and physicians and hear their stories always reminded me that the work we’re doing really makes a difference,” Jeff told the magazine. That work ultimately led to his founding of Paragon Biosciences, described by Insights Care as “a pioneer in venture innovation” that “invests in and incubates high-growth biotechnology companies.”

Since October 2017, Paragon has invested over $450 million in pharmaceutical compounds and built high growth biopharmaceutical companies aimed at directly at developing treatment for those in need.

Paragon’s portfolio companies include Castle Creek Pharma, Harmony Biosciences, Skyline Biosciences and Emalex Biosciences, and are committed to finding treatments for patient needs not addressed by larger pharmaceutical companies. Jeff notes that, while the FDA approval process can be arduous, Paragon’s model works because it is based on a “focused strategy that puts patients first and addresses true unmet needs.” Paragon plans to continue investing in this vision through over $445 million in planned capital deployment in the next 12 months.

Jeff credits his success to key leadership principles, including his ability to recruit and maintain a team committed to the same vision. In fact, many of his staff have stayed with him for over 15 years. “Our scientists are putting in years of dedication into research, and there are many patients who desperately need these medications,” Jeff told the magazine.

Despite the taxing persistence needed to achieve the success realized by Jeff and Paragon, the company’s leader told the magazine “the most rewarding thing is when you hear that a drug you brought to market is improving or saving someone’s life.”

The full article can be found here: https://insightscare.com/jeff-aronin-innovative-entrepreneur-putting-patients-first/

About Paragon Biosciences
Paragon Biosciences, LLC improves the lives of patients suffering from debilitating diseases by building innovative biotechnology companies which bring important treatments to the market. Paragon's portfolio companies are managed by healthcare industry leaders and biotech entrepreneurs committed to improving outcomes for patients. Paragon's leadership and management team leverage their entrepreneurial experiences and their expertise to develop and finance biotechnology companies and accelerate their advancements. Paragon Biosciences is headquartered in Chicago, Illinois. For more information, visit: http://www.paragonbiosci.com

Read the full story at https://www.prweb.com/releases/jeff_aronin_named_one_of_the_20_most_influential_leaders_in_healthcare_for_2018/prweb15803394.htm.


'/>"/>
Source: PRWeb
Copyright©2018 Vocus, Inc.
All rights reserved


Related biology news :

1. Dickinson Wright Attorney Lance Anderson Named Pharmaceuticals and Biotechnology Practice Group Chair
2. RxS LLC Principal Named to PharmaVOICE 100 Most Inspiring People
3. Stephen Zarrilli Named President & CEO of University City Science Center
4. Visikol Co-Founder Michael Johnson named to 2017 Forbes 30 Under 30 List
5. MedNet Solutions Named Most Outstanding eClinical Solutions Company
6. ACMG Annual Clinical Genetics Meeting Named One of the Fastest Growing Meetings in USA for Fourth Time
7. MedNet Solutions Named A Finalist For The 16th Annual Tekne Awards
8. NXT-IDs Wocket Smart Wallet Named Number One Best Tech Gift for 2015 by Rethink Modern
9. A new land snail species named for equal marriage rights
10. CIFAR fellows named to Thomson Reuters list of Nobel-caliber scientists
11. BIDMC researchers named among the most influential scientific minds
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2018)... ... October 11, 2018 , ... ... vision behind the National Institute for Innovation in Manufacturing Biopharmaceuticals (NIIMBL). The Institute, ... designed to advance biopharmaceutical manufacturing and workforce development in the United States. Biopharmaceuticals ...
(Date:10/5/2018)... (PRWEB) , ... October 04, 2018 , ... High dose ... some of the tests such as cardiac troponin has serious clinical complications. There is ... the exact prevalence is still unknown. , High dose of biotin supplement use ...
(Date:10/2/2018)... ... 02, 2018 , ... Stuart is a fun-loving eight-year-old Labrador retriever. Like many labs, Stuart’s ... “He loves playing ball so much that whenever anyone comes to our door, he grabs ... of fetch.” In early 2017, Stuart began limping and eventually could no longer play ...
Breaking Biology News(10 mins):
(Date:10/2/2018)... , ... October 02, 2018 , ... ... ignored, contamination endangers the reliability and reproducibility of experimental data. Each lab must ... In this educational webinar, which is sponsored by Eppendorf , attendees will ...
(Date:9/28/2018)... NEW YORK (PRWEB) , ... September 28, 2018 ... ... Medical Laboratory Services (PMLS) to increase the availability of the GlycoMark test, the ... patients with diabetes. With the partnership, PMLS will promote and offer the GlycoMark ...
(Date:9/27/2018)... ... 2018 , ... Consumers adopting new health care technologies like ... to a new Zeldis Research and Schlesinger Group study, “The Consumerization of Health ... of fitness and health wearables, remote monitoring, patient portals and other convenience products ...
(Date:9/27/2018)... ... September 27, 2018 , ... This past weekend ... SureAdhere Mobile Technology, Inc. announced they will formally merge companies and integrate their ... tuberculosis (TB) and other diseases. These two social enterprise corporations, both of which ...
Breaking Biology Technology: